secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2026-09-28T20:05:14+00:00
Accession:  0001818382-26-000011
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Humacyte adds Scott Coward and Paul Kuznik to board ahead of planned ATEV dialysis launch
--------------------------------------------------------------------------------

- Board appointed Scott Coward (Class I, term to 2028, Audit Committee) and Paul Kuznik (Class II, term to 2029, Commercial Committee) on September 22, 2026.
- Coward was EVP, Chief Legal Officer and CAO of Exact Sciences from January 2015 to December 2022 and led the Genomic Health integration; he has been an attorney at K&L Gates since July 2026.
- Kuznik was CEO of Bolton Medical (2015-2018) through its acquisition by Terumo, then President of Terumo Aortic North America from 2020 to 2023.
- Each director receives a $50,000 annual cash retainer, $5,000 per committee, and an option for 125,000 HUMA shares under the non-employee director program.
- CEO Laura Niklason cited the additions as Humacyte expands the Symvess launch and prepares the ATEV commercial launch for dialysis access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838226000011/0001818382-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838226000011/huma-20260922.htm
  HTML page:      https://secwatch.observer/filing/0001818382-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer